Sebetralstat
Brand names: Ekterly · Active ingredient: Sebetralstat
In short: EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
What is Sebetralstat used for?
EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Sebetralstat dosage
The recommended dosage of EKTERLY is one dose of 600 mg (two tablets) orally at the earliest recognition of an acute HAE attack.
A second dose of 600 mg (two tablets) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur.
Maximum recommended dosage is 1,200 mg (four tablets) in any 24-hour period.
Refer to Table 1 for dosage modification of EKTERLY when used concomitantly with CYP3A4 inhibitors and inducers.
Dosage Modification for Concomitant use of EKTERLY with CYP3A4 Inhibitors
Strong CYP3A4 Inhibitors | Avoid concomitant use with EKTERLY.
Moderate CYP3A4 Inhibitors | Reduce EKTERLY dosage to 300 mg (one tablet) orally at earliest recognition of an acute HAE attack.
A second dose of 300 mg (one tablet) may be taken at least 3 hours after first dose if response is inadequate or if symptoms worsen or recur .
Weak CYP3A4 Inhibitors | No dosage modification of EKTERLY .
Dosage Modification for Concomitant use of EKTERLY with CYP3A4 Inducers
Strong and Moderate CYP3A4 Inducers | Avoid concomitant use with EKTERLY.
Weak CYP3A4 Inducers | No dosage modification of EKTERLY .
Refer to Table 2 for recommended dosage of EKTERLY in patients with hepatic impairment.
Recommended Dosage of EKTERLY in Patients with Hepatic Impairment
Severe Hepatic Impairment (Child-Pugh Class C) | Avoid use of EKTERLY .
Moderate Hepatic Impairment (Child-Pugh Class B) | Recommended dosage of EKTERLY is one dose of 300 mg (one tablet) orally at the earliest recognition of an acute HAE attack. A second dose of 300 mg (one tablet) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur .
Mild Hepatic Impairment (Child-Pugh Class A) | Recommended dosage is the same as the recommended dosage in patients with normal hepatic function .
How to take Sebetralstat — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Patient Information).
Dosage Modification for Strong and Moderate CYP3A4 Inhibitors
Advise patients not to use EKTERLY with strong CYP3A4 inhibitors . When used concomitantly with moderate CYP3A4 inhibitors, advise patients to reduce dose to one tablet of 300 mg (total dose 300 mg) at the earliest recognition of an HAE attack. A second dose of 300 mg (one tablet) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur .
Recommended Dosage in Patients with Hepatic Impairment
Advise patients with severe hepatic impairment to avoid use of EKTERLY. In patients with moderate hepatic impairment, advise patients to take one tablet of 300 mg (total dose 300 mg) at earliest recognition of an HAE attack. A second dose of 300 mg (one tablet) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur .
For more information, visit www.EKTERLY.com
EKTERLY® is a registered trademark of KalVista Pharmaceuticals Limited.
Distributed by:KalVista Pharmaceuticals, Inc.200 Crossing BoulevardFramingham, MA 01702
Warnings & precautions
Do not take this medicine if: None.
Sebetralstat side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of EKTERLY is based on data from a double-blind, randomized, placebo-controlled, three-way, crossover clinical trial (KONFIDENT) . In KONFIDENT, a total of 110 patients aged 12 years and older with HAE treated 264 attacks. In the safety population, 93 patients received EKTERLY 600 mg, 86 patients received EKTERLY 300 mg, and 83 patients received placebo. While EKTERLY 300 mg was included in KONFIDENT, the safety data is based on the recommended dosage of EKTERLY 600 mg.
Table 3 displays adverse reaction(s) with an incidence of ≥2% in the EKTERLY 600 mg treated patients and more common than placebo.
aOne (1) patient assigned to administer placebo actually received EKTERLY 600 mg. Safety results are presented by actual treatment received.
Adverse Reaction | EKTERLY 600 mg (N = 93) | Placebo (N = 83)a
n (%) | n (%)
Headache | 3 (3.2) | 1 (1.2)
Drug interactions
Strong CYP3A4 Inhibitors
Avoid use of EKTERLY with strong CYP3A4 inhibitors .
Sebetralstat is a substrate of CYP3A4. Concomitant use of sebetralstat with a strong CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions.
Moderate and Weak CYP3A4 Inhibitors
Reduce dose of EKTERLY to one dose of 300 mg (one tablet) orally at the earliest recognition of an HAE attack when used concomitantly with moderate CYP3A4 inhibitors. A second dose of 300 mg (one tablet) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur .
Sebetralstat is a substrate of CYP3A4. Concomitant use of sebetralstat with a moderate CYP3A4 inhibitor increases sebetralstat exposure, which may increase the risk of sebetralstat adverse reactions.
No dose modification is recommended when EKTERLY is used concomitantly with a weak CYP3A4 inhibitor .
Strong and Moderate CYP3A4 Inducers
Use of EKTERLY with strong or moderate CYP3A4 inducers is not recommended.
Sebetralstat is a substrate of CYP3A4. Concomitant use of sebetralstat with a strong or moderate CYP3A4 inducer decreases sebetralstat exposure, which may decrease efficacy. …
About this medicine
The active ingredient of EKTERLY is sebetralstat, a plasma kallikrein inhibitor. The chemical name of sebetralstat is N-[(3-fluoro-4-methoxypyridin-2-yl) methyl]-3-(methoxymethyl)-1-({4-[(2-oxo-1,2-dihydropyridin-1-yl) methyl]phenyl}methyl)-1H-pyrazole-4-carboxamide. The chemical structure of sebetralstat is:
The molecular formula is C
26
H
26
FN
5
O
4
and molecular weight is 491.5. Sebetralstat is a white to off-white crystalline powder. It is slightly soluble in ethanol, acetone and isopropanol, and practically insoluble in water.
EKTERLY is supplied as 300 mg film-coated tablets for oral administration. Each tablet contains the active ingredient sebetralstat. The inactive ingredients include croscarmellose sodium, glycerol mono and dicaprylocaprate, guar gum/guar galactomannan, hypromellose, iron oxide black, iron oxide yellow, macrogol polyvinyl alcohol graft copolymer, magnesium stearate, maltodextrin, medium chain triglycerides, microcrystalline cellulose, polyvinyl alcohol, povidone, talc and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1d145e2f-8e7e-2e90-e063-6294a90a4449. Read the full official label on DailyMed.